Remise des prix du concours organisé par ALLIS-NA et la Région Nouvelle Aquitaine dans le cadre du road show cancer “De la Recherche à la prise en charge du patient” lors du salon NOVAQ 2018 à Bordeaux. Le dispositif ONCOGRAMME® d’@Oncomedics gagne le prix “DISPOSITIF...
https://www.novaq.fr/ Le Jeudi 13 septembre, à 14h35, Christophe Lautrette, Président d’Oncomedics, présentera l’Oncogramme®, dans la cadre du salon des innovations développées dans la région Nouvelle Aquitaine [Hangar 14 à Bordeaux)...
This test is currently at the patient’s expense but Oncomedics is actively working to obtain its reimbursement.
Our mission is to extract the maximum of information from a fresh human tumor leading to the best possible treatment for the immediate benefit of the patient.
Despite great advances in our understanding of the cellular and molecular bases of human cancers and the increasing number of new therapeutic options, the treatment of advanced human cancers frequently remains disappointing, particularly when facing metastases.
This is linked to the natural history of the tumors and/or patients, considering (i) the interpatient variability in drug exposure, (ii) the diversity of cancer subtypes with respect to molecular profiles, and (iii) the intratumoral heterogeneity, and (iv) the highly variable tumor cell doubling time. All these sources of variability make difficult the validation of markers predictive of the clinical response to the different therapeutic options including surgery, chemotherapy, targeted therapy, immunotherapy or radiotherapy.
The interest of patient tumor established primary cell culture in preclinical and clinical testing is growing with the increasing number of new therapeutic alternatives. These primary cell cultures directly derived from patient tumor samples, with limited in vitro manipulation, provide a more accurate depiction of human tumor biologic characteristics than cell lines with high numbers of in vitro doubling periods.
The unique experience of Oncomedics allows the investigation of the sensitivity profile of the primary tumor cells anticipating the correlation with the clinical situation for each individual patient.
Oncomedics has secured all the legal and regulatory processes to collect and cultivate the fresh human tumors in a full legal frame. To facilitate these processes for his customers, Oncomedics has developed a proprietary platform OncoTRIP, which has integrated all the required successive steps. With all these efforts, Oncomedics provides a full and flexible analysis of the primary cultures of human tumors. In addition to this platform OncoTRIP, using its unique know-how, Oncomedics has built a bank of living primary tumor cells and has optimized specific culture media to increase viability and growth of primary cells (OncoMiD-Via, OncoMiD-Diss, OncoMiD).
In addition to these services, Oncomedics develops its own pipeline of new primary cell culture products and services to extend the levels of investigation of the fresh human tumor cells. Oncomedics is advancing its portfolio of Research and Development projects (BioCaptor, IMODI, Oncogramme) on its own or through collaborative efforts with prestigious partners from the industrial world (Sanofi, Servier, Pierre Fabre, Ipsen, Transgene, Oncodesign, CTI-Biotech, ArianaPharma, Biofortis…) or from the academic institutions (Universities, CNRS, Inserm…).
The figure below summarizes all the scientific and strategic interests of Oncomedics to use the primary tumor cell cultures in a “clinical like trial” generating data potentially representative of the clinical trial results.
